Evidence of apoptosis in human carotid atheroma  by Konstadoulakis, M.M. et al.
733
Apoptosis plays an important role in the regula-
tion of tissue development, differentiation, and
homeostasis.1 Apoptosis differs morphologically
from necrosis because cells exhibit cytoplasmic and
nuclear condensation and then fragment into apop-
totic bodies without membrane disruption. The
apoptotic bodies then undergo phagocytosis by
neighboring cells or macrophages without inducing
an inflammatory response.2,3 Apoptosis has been
studied extensively for its role in the immune
response, tumor cell growth and regulation, and
many other physiologic processes, such as the devel-
opment of cartilage bone and gut and the remodel-
ing of limb buds.4,5 Only a few studies have linked
apoptosis to the cardiovascular system. 
Excessive accumulation of cells in the intima is
believed to be a major cause of disease progression in
atherosclerosis.6,7 This cell accumulation is attributed
to an increased migration, to a proliferation of smooth
muscle cells (SMCs), monocytes/macrophages, and T
lymphocytes,8 or to both. Within the sclerotic region
of the human atheromatous plaque, a low density of
cells with some appearance of cellular debris is found.
The process by which a cellular lesion evolves into an
acellular sclerotic lesion is poorly understood but pre-
sumably involves extracellular matrix synthesis and cell
deletion and could be initiated by a process caused by
apoptosis. Apoptosis requires the expression of a spe-
cific set of genes, such as BCL2 and related genes.9,10
The product of the BCL2 gene, when elevated in cells,
in vivo or in vitro, prevents the normal course of cell
Evidence of apoptosis in human carotid
atheroma
M. M. Konstadoulakis, MD, PhD, G. D. Kymionis, MD, PhD, M. Karagiani,
MD, PhD, V. Katergianakis, N. Doundoulakis, MD, PhD, V. Pararas, A.
Koutselinis, MD, PhD, M. Sehas, MD, and P. Peveretos, MD, Athens, Greece
Purpose: Apoptosis is a morphologically distinct form of programmed cell death that
plays a major role in cellular development and homeostasis. In this study, we examined
the role that apoptosis may have in the pathogenesis of atherosclerosis.
Methods: We examined immunohistochemically 20 normal carotid arteries and the carotid
arteries of 86 patients (mean age, 68 years; range, 52 to 80 years) who underwent
atherectomy for primary atherosclerosis. The expression of two genes, BCL2, which
inhibits apoptosis, and BAX, which induces apoptosis, was examined and correlated to
the presence of risk factors that included hypertension, smoking, hyperlipidemia, and
diabetes mellitus.
Results: BAX expression was found in 26 of 86 cases (30%), and no immunoreactivity
was found in the normal carotid specimens. BCL2 expression was not seen in any exam-
ined tissues (atherosclerotic or normal carotid arteries). Of the 26 patients who
expressed the BAX gene, 22 were hypertensive (85%), and hypertension (>160/95 mm
Hg) was present in 25 of 60 patients (41%) who did not express the BAX gene (p <
0.01). No significant correlation was found between the expression of the BAX gene and
other risk factors (smoking, hyperlipidemia, diabetes mellitus) or presenting symptoms.
Conclusions: In a significant number of stenosed carotid arteries (30%), we found no evi-
dence of apoptosis suggested by the presence of BAX expression. Hypertension was
more prevalent in those patients with BAX gene expression than in those patients with-
out BAX gene expression. BCL2 expression, which inhibits apoptosis, was not found.
Further study of this phenomenon may contribute to the discovery of new treatments
for atherosclerosis. (J Vasc Surg 1998;27:733-9.)
From the Molecular Immunology Laboratory (Drs. Konstadoulakis,
Kymionis, and Karagiani), the First Department of Propedeutic
Surgery (Katergianakis, Pararas, and Peveretos), and the Third
Department of Surgery (Sehas), Medical School of Athens,
Hippokration Hospital; the Department of Vascular Surgery, Red
Cross Hospital of Athens (Dr. Doundoulakis); and the
Department of Forensic Medicine, University of Athens
(Koutselinis).
Reprint requests: M. M. Konstadoulakis, MD, PhD, Kalvou 24,
15452 Psyhiko, Athens, Greece
Copyright © 1998 by The Society for Vascular Surgery and
International Society for Cardiovascular Surgery, North
American Chapter.
0741-5214/98/$5.00 + 0 24/1/87947
death that is induced by trophic factor deprivation or
other stimuli without altering proliferation.11 Recently
several other proteins that are homologous to BCL2
have been isolated, and their complementary DNAs
have been cloned.10 One of these proteins is encoded
by BAX and counteracts the effect of BCL2 on cell
survival. The BCL2 to BAX ratio has been proposed
to determine whether a cell undergoes apoptosis.12,13
In this study, we examined the BAX and BCL2
expression in patients with atherosclerosis to estab-
lish a possible role for these genes in the pathogen-
esis of this disease. 
MATERIALS AND METHODS
Arterial specimens. Atherosclerotic plaques
from human carotid arteries with atherosclerosis
were obtained from patients who underwent carotid
endarterectomy. All patients had stenosis >75%. The
degree of stenosis was estimated directly with duplex
examination. Peak systolic velocity that was more
than 250 cm/sec, end diastolic peak velocity that was
more than 100 cm/sec, and internal carotid/com-
mon carotid peak velocity ratio that was more than
1.8 were used to determine a >75% stenosis.
Additional angiography was performed in several
patients to ensure the result of duplex examination. 
Patient records were reviewed to identify a vari-
ety of information that included age, gender, pres-
ence of risk factors (hypertension, smoking, hyper-
lipidemia, and diabetes mellitus), and presenting
symptoms.
Twenty samples of normal carotid arteries, which
were obtained from the Department of Forensic
Medicine at the University of Athens, were used as
controls. All of the samples were retrieved from per-
sons with an average age of 18 years (range, 17 to 19
years) who died in car accidents with no medical his-
tory and no atherosclerotic changes in autopsy. 
All specimens were placed in fresh 4% (wt/vol)
paraformaldehyde immediately after retrieval. After
2 hours the tissue was transferred to a 30% sucrose-
phophate buffer solution and then embedded in
paraffin. For each tissue specimen, several 4 m m sec-
tions were cut. One section from each specimen was
stained with hematoxylin and eosin for conventional
light microscopic analysis.
Immunohistochemical analysis. Paraffin tissue
sections (5 m m) were mounted on polylysine-coated
glass slides. Paraffin was removed from the slides
when heated at 60° C for 10 minutes and then
washed three times in xylene for 10 minutes each.
After gradual hydration through graded alcohols,
the sections were rinsed in distilled water for 5 min-
utes. Slides then were incubated for 30 minutes in
0.3% hydrogen peroxide in methanol to quench
endogenous peroxidase activity. The sections were
incubated in citrate buffer (0.01 mol/L: pH 6.0) for
two 5-minute cycles in a microwave oven for antigen
retrieval. For localization of the BCL2 and BAX pro-
tein, the sections were incubated for 60 minutes at
room temperature with a 1:40 dilution and 1:1000
dilution, respectively, of the monoclonal antibody
(Dakopatts, Glostrup, Denmark) and visualized by
the indirect avidin-biotin procedure with 3,3-
diaminobenzidine tetrahydrochloric as the substrate
chromogen. The immunostained slides were coun-
terstained with hematoxylin for 1 minute. 
Normal lymph node tissue represented positive
control for BCL2 immunostaining, and sections of
normal breast epithelium that were positive for
BAX expression were included as positive controls
for BAX. Each positive control was consistently pos-
itive. Negative controls for BCL2 and BAX were
obtained by substituting the primary antibody with
the immunoglobulin fraction of nonimmune mouse
serum. Negative control sections were unstained.
Light microscopic analysis. On conventional
hematoxylin-eosin stained sections, apoptotic cells
were identified by the presence of pyknotic nuclei
and nuclear fragments.14 The cells were isolated
from neighboring cells as a result of the disruption
of intercellular interactions. To verify that BAX gene
had been expressed in apoptotic cells and to corre-
late the extent of apoptosis to the expression of
BAX gene, sections that were consecutive to those
stained with BAX antibody were stained with con-
ventional hematoxylin-eosin stained sections (Fig. 1,
B) and compared with sections that expressed the
BAX gene (Fig. 1, A).
Histologic analysis for immunostaining. All
slides were evaluated for immunostaining in a blind
fashion by a pathologist without knowledge of other
clinopathologic data. Staining for both BCL2 and
BAX was classified visually into a grading system on
the following four-point scale: no staining present in
any of the cells (-), weak staining in less than 20% of
SMCs and macrophages (+), moderate staining in
20% to 50% of SMCs and macrophages (++), and
intense staining in more than 50% of the cells (+++).
To test the repeatability of this classification, anoth-
er investigator evaluated the same slides without
knowledge of the former classification or other data.
Most of the slides (97%) were classified similarly by
both investigators. When the investigators disagreed
on a section, the views of a third pathologist were
taken into consideration.
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From the atherectomy specimens, comparable
areas were selected by cell type and cell number, which
distinguished the following areas: macrophage/mono-
cyte–enriched areas that displayed macrophage cells,
foam cells, and other inflammatory cells; myxomatous
areas that contained SMCs; and collagen-enriched
sclerotic areas of low cellular density that were
enriched with a dense sclera-like collagenous matrix.
Because atherosclerotic lesions are extremely het-
erogenous in nature, we selected these regions for
comparative analysis. 
Statistical analysis. Statistical comparison of
the immunostaining results with the presence of risk
factors (hypertension, smoking, hyperlipidemia, and
diabetes mellitus) and the presenting symptoms was
performed by c 2 analysis.
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Fig. 1. A, Expression of BAX gene (arrows) in a section of atheromatous carotid artery (· 10).
B, Consecutive section stained with haematoxylin-eosin (· 10). A correlation exists between
expression of BAX gene and identification of apoptotic morphologic changes (arrows).
A
B
RESULTS
We found that 26 of 86 cases (30%) expressed
the BAX gene. Of these 26 cases, 9 cases (34.6%)
had slight staining (+), 16 cases (61.5%) had moder-
ate staining (++), and 1 case (3.9%) had intense
staining for BAX protein.
A correlation between the expression of BAX
gene (Fig. 1, A) and the identification of apoptotic
morphology changes, pyknotic nuclei and nuclear
fragments (Fig. 1, B) was found in all sections and
regions that expressed the BAX gene. In sections
that were unstained for BAX expression, both nor-
mal and atherosclerotic arteries, we found no apop-
totic morphology in cells. 
Quantitative analysis revealed that the myxoma-
tous area and the macrophage-enriched regions rep-
resented 30% of the lesion area and the remaining
70% of the hypocellular sclerotic area. The expression
of BAX gene was area-dependent. In myxomatous
areas, the expression of BAX gene was approximate-
ly 10% to 30% of SMCs (Fig. 2), and in macrophage-
enriched regions, the BAX gene expression was
observed in 30% to 40% of macrophages (Fig. 3).
None of the 20 samples of normal carotid arter-
ies were BAX immunopositive. Not one of the
examined tissues, both normal and atherosclerotic,
was BCL2 positive. 
A comparison of these findings with the presence
of risk factors, including hypertension, smoking,
hyperlipidemia, and diabetes mellitus, showed a sig-
nificant correlation only between BAX expression
and hypertension. In our sample, 47 patients (55%)
were hypertensive (>160/95 mm Hg), 40 (47%)
were smokers, 11 (13%) had diabetes mellitus, and
15 (17%) had hyperlipidemia. Of the 26 patients
who expressed the BAX gene, 22 were hypertensive
(85%), and hypertension was present in 25 of 60
patients (41%) who did not express the BAX gene 
(p < 0.01). No significant correlation was found
between the expression of the BAX gene and the
other risk factors of atherosclerosis. 
Table I shows the correlation between the extent
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Table I. Correlation between the extent of BAX gene expression and the risk factors
Extent of BAX expression No (26) Hypertension (22) Smoking (12) Diabetes (3) Hyperlipidemia (4)
Weak (+) 9 6 3 1 1
Moderate (++) 16 15 9 2 3
Intense (+++) 1 1 0 0 0
p = 0. 18 p = 0. 39 p = 0. 93 p = 0. 80
Fig. 2. Expression of BAX gene in smooth muscle cells (brown cytoplasm) of atheromatous
carotid artery (· 40).
of BAX expression and the risk factors. No signifi-
cant correlation was found between the extent of
BAX gene expression (weak, moderate, intense) and
risk factors, such as hypertension (p = 0.18), smok-
ing (p = 0.39), diabetes mellitus (p = 0.93), and
hyperlipidemia (p = 0.80).
The following presenting symptoms preceded
each operation: transient ischemic attack in 40
patients (47%), amaurosis fugax in 22 patients
(26%), cerebrovascular accident in 9 patients (10%),
and no symptoms in 15 patients (17%). The expres-
sion of BAX gene was correlated with these present-
ing symptoms, and no significant correlation was
found (Table II).
DISCUSSION
Intimal thickening has an important role in the
proliferation of SMCs.15 In the last decade, we have
learned a great deal about growth factors and
cytokines that promote SMC proliferation.16 Yet
advanced atherosclerotic lesions, such as atheroma,
contain few proliferating cells.17 Analysis of prolifer-
ation markers reveals a low rate of SMC proliferation
that is similar to that of macrophages, which are the
major cellular components of human atherosclerotic
lesions. 
The initial cell migration and proliferation that is
a result of injury to the vessel is believed to be a
major cause of vascular disease.6 However, the accu-
mulation of cells in the intima theoretically is the
sum of cell migration and cell growth. Cell death
and alteration of any of these events could affect the
disease process. Apoptosis has been seen, for
instance, in normal endothelial cells. The cycle of
growth, remodeling, regression, and decay has been
documented in aortic endothelial cells and SMCs of
the incisal artery during tooth development.
Recently the regulation of c-myc expression has been
found to induce apoptosis in rat vascular SMCs.18
The BCL2 proto-oncogene was identified origi-
nally from a human chromosomal translocation that
predisposed affected individuals to malignant trans-
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Table II. Correlation between the extent of BAX gene expression and the symptoms
Extent of BAX expression No (26) TIA (13) AF (10) CVA (2) ASX (4)
Weak (+) 9 5 2 1 2
Moderate (++) 16 7 7 1 2
Intense (+++) 1 1 1 0 0
p = 0. 14 p = 0. 28 p = 0. 23 p = 0. 59
Fig. 3. Expression of BAX gene in macrophages (brown cytoplasm) of atheromatous carotid
artery ( · 40).
formation of immune cells. Increased expression of
BCL2 enhances the cellular survival of immune
cells,19,20 hematopoetic cells,21 and neurons.22
Bennett et al.23 showed that human vascular SMC
apoptosis is suppressed by the expression of the
BCL2 gene. The BCL2 product is a membrane-asso-
ciated protein that suppresses apoptosis in several
different cell types. The mechanism of BCL2 action
is unknown, but BCL2 expression can inhibit apop-
tosis because of free radicals and lipid peroxidation,
both of which are implicated in atherogenesis.24
Recently several other proteins that are homologous
to BCL2 protein have been isolated, and their com-
plementary DNAs have been cloned.9,10 As one of
these proteins, BAX product is induced by growth
factor depletion10 and promotes apoptosis. The
homology among the BCL2-related proteins is con-
centrated in two domains, BH1 and BH2, that are
required for their dimerization and function.25
In this study, we examined the possibility that
apoptosis, in addition to cell proliferation, con-
tributes as an important independent factor to the
pathologic changes of human atheromatous lesions.
We came to this conclusion by studying the expres-
sion of two genes, BCL2, which inhibits apoptosis,
and BAX, which induces apoptosis. BAX expression
was found in 26 of the 86 cases (30%). Depending
on the type of the lesion (macrophage-rich or myx-
omatous area), 10% to 30% of SMCs (Fig. 2) and
30% to 40% of macrophages (Fig. 3) expressed the
BAX gene. No immunoreactivity was seen in the
normal carotid specimens. On the contrary, BCL2
expression was not seen in atherosclerotic arteries or
normal carotid arteries. Han et al.26 reported similar
results that showed that 10% of the cells in sclerotic
lesions and 46% of the cells in the macrophage-rich
area are TUNEL+ as found by in situ DNA end-
labeling method. Geng and Libby27 reported evi-
dence for apoptosis in coronary and carotid athero-
ma at the same rates. Also with an in vitro approach,
Bennett et al.23 reported a higher rate of apoptosis
in SMCs that were derived from human atheroma as
compared with those from normal arteries. 
Isner et al.28 demonstrated that apoptosis is found
more frequently in restenosis than in primary human
vascular lesions. This finding is consistent with the
notion that the restenotic lesions are typically more
proliferate than primary lesions. In our study, similar
findings were not seen because the rate of restenosis
in carotid arteries is very small. Furthermore, attempts
to augment apoptosis after a balloon injury constitute
a theoretical approach to the prevention of restenosis.
One such strategy that is currently under investigation
involves transfecting SMCs with the so-called ICE
gene, which increases apoptosis in cells, or with other
genes to expedite programmed cell death. This phe-
nomenon may contribute to the discovery of new
treatments for atherosclerosis.
We were able to demonstrate that apoptosis is
present in 30% of human atherosclerotic lesions and
that the major cell types that undergo apoptosis are
apparently SMCs and macrophages. These findings
suggest that, in addition to cell migration and pro-
liferation, apoptotic cell death also influences the
progression of atherosclerosis. The identification of
factors that influence the level of apoptosis in the
human atherosclerotic lesion should contribute to a
better understanding of vascular disease progression.
In our study, a significant correlation (p < 0.01)
between expression of the BAX gene and patients
with hypertension was found. No similar correlation
was observed between the BAX gene and the other
risk factors. 
Atherosclerotic lesions that contain a high level
of apoptotic cells, such as the areas enriched in
macrophages within granulation tissues, may also
represent regions of active vascular wound remodel-
ing. Apoptosis is possibly a part of normal vascular
wound healing, whereas dysregulated apoptosis and
inefficient removal of apoptotic bodies may con-
tribute to the progression of the atherosclerotic
plaque and increase the severity of the disease. Thus
excessive apoptosis without appropriate phagocyto-
sis may contribute to additional macrophage recruit-
ment and secretion of inflammatory cytokines. This
contribution may induce increased cellular migra-
tion, proliferation, and other disease-complicating
factors, such as the release of oxidized lipids that
exacerbate the severity of atherosclerotic lesions. 
These data highlight a role for apoptosis in
human atherosclerosis. Our results and those results
that emerge from other laboratories broaden the tra-
ditional view that emphasizes the role of cell prolif-
eration in atheromatosis. Apoptosis may have an
important and independent role in the contribution
of those pathologic changes that are characteristic of
advanced atherosclerotic lesion. The pathobiology
of human atherosclerosis should consider apoptosis
as a novel mechanism that participates in plaque evo-
lution. Further study of this phenomenon may con-
tribute to the discovery of new treatments, such as
gene therapy, for atherosclerosis.
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